

Poster #	ECP	First Name	Last Name	Organization	Paper Title
1		Olufunso	Abosedede	DEPARTMENT OF CHEMISTRY, FEDERAL UNIVERSITY OTU	AI in Medicinal Chemistry: From Machine-Learning-Based Chemical Prediction to the Future of AI-Enabled Metal-Based Drug Discovery
2		Marta	Acebron Garcia De Eula	Astrazeneca	Mass photometry as a cost- and time-efficient pre screen for PROTAC-mediated ternary-complex
3	ECP	Laurine	Achimo	University Of Leeds	Optimisation and use of a Polyethylene Glycol (PEG) precipitation assay to probe the biophysical properties of proteins
4	ECP	Nikita	Admane	BITS Pilani K.K. Birla Goa Campus	PHYTOCHEMICALS AS PUTATIVE THERAPEUTIC DRUGS FOR TARGETING THE AMYLOID MATRIX OF ANTIBIOTIC RESISTANT STAPHYLOCOCCAL BIOFILMS
5		Louise	Affleck	Revvity	Novel Time-Resolved Fluorescence Plate-Based Assay for Antibody and ADC Internalisation Analysis
6	ECP	Pallavi	Agarwal	Michigan State University	Small Molecules, Big Moves: Dipeptides rewire glycolysis through dual inhibition of PKM2 and LDHA
7	ECP	Waheed	Ahmed	School Of Pharmaceutical Sciences (fcf), University Of Sao Paulo	CHEMICAL-GENETIC SCREENING IDENTIFIES CYCLOPIAZONIC ACID-SENSITIVE CALCIUM STORES AS A POTENTIAL ANTIMALARIAL TARGET IN PLASMODIUM FALCIPARUM
8	ECP	Nisha	Airra	University Of Exeter	Developing a novel drug therapy for Neurofibromatosis type 1 tumours
9	ECP	Sofie	Albinsson Högborg	Astrazeneca	Improving room-temperature stability of one step qPCR plates to enable reliable automated high throughput screening
10	ECP	Beth	Albone	RxCelerate / Newcastle University	RxSite: A Flexible and Customisable Hotspot Mapping Platform for Fragment-Based Binding-Site Discovery
11		Alaa	Aldamegh	Newcastle University	Flavonoid synergists re-sensitise clinical MDR Mycobacterium abscessus isolates to antibiotic Activity
12	ECP	Michael	Alexander	Revvity	Integrating Functional Genomics and Phenotypic Profiling to Deconstruct RAS Inhibitor Mechanisms of Action and Resistance
13	ECP	Farooq	Ali	UNIVERSITY OF SAO PAULO	Th1 immunity is associated with Staphylococcus chromogenes intramammary infection
14		Helena	Almqvist	Pelago Bioscience	Unlocking challenging targets with the CETSA® technology platform
15	ECP	Noura	Alolyani	Uol	"Targeting senescence as an anticancer therapy through α V β 3 integrin, using the 'one-two punch' approach"
16		Daniel	Alpern	Alithea Genomics	Multi-Omics Integration of Transcriptomics and Phenomics Reveals Complementary Molecular and Morphological Signatures of Compound Response and Toxicity
17	ECP	Ibraheem	Al-qaraghuli	University Of Sunderland	Exploring FABP5 as a Therapeutic Target in Psoriasis: From Target Validation to Pharmacological Modulation
18	ECP	Ali	Amer	University of Sunderland	Evaluation of the Anti-Inflammatory Potential of Oleocanthal Nanoparticles Combined with Tacrolimus as a Potential Therapeutic Strategy for Psoriasis.
19		Nader	Amin	JEOL	JASON AffinityScreen: Automated Analysis of NMR Fragment-Based Screening Data
20	ECP	Laura	Andraghetti	Transition Bio	Live suspension cell imaging of YTHDC1 biomolecular condensates enables discovery of potent and selective inhibitors
21	ECP	Richard	Anozia	University Of Nottingham	DEVELOPING NOVEL BIFUNCTIONAL COMPOUNDS FOR TARGETED CXCL12 CHEMOKINE RECEPTOR 2 (CXCR2) DEGRADATION
22	ECP	Aude	Aravinthan	University Of Nottingham	GRK-dependent trafficking of NK1R and its impact on subcellular signalling dynamics
23	ECP	Georgina	Archer	Functional Genomics Centre	3D Models - Using Disease Relevant Models for Target Discovery
24		S Neha	Ashraf	Astrazeneca	A molecular stabiliser of an inhibitory eIF2B-eIF2(α P) complex activates the Integrated Stress Response
25	ECP	Grace Adeola	Atobatele	University of Staffordshire	Transcriptomic Signatures of Metformin Action Under Hypoxia in Prostate Cancer Cells
26		Lawrence	Atupem	Aurora Microplates	CELLAZIP: Cyclo Olefin Polymer Microplates with a newly developed synthetic scaffold for high cell adhesion and proliferation
27		Gemma	Baillie	Bioascent	Using Label-Free Technologies to Characterise the Pharmacology of the Mas-Related GPCR Family Member D (MRGPRD) Receptor

28 ECP	Grace	Bamford	Z7 Biotech Ltd	SolThermoBRET: Ligand-induced stabilisation of soluble proteins
29 ECP	WEIYE	Bao	Scripta Therapeutics	Multimodal Integrative Framework for Protein–Protein Interaction Prediction
30 ECP	Naomi	Barrett	University Of Nottingham	Real-time ERK signalling of the RET receptor in response to GDNF family ligands
31 ECP	Elizabeth	Bateman	University Of Oxford	Chemical Biology Tools to Assess the Functional Ligandability & Enable Rational Ligand Design of Intrinsically Disordered Proteins
32 ECP	Liana	Bauer	Karlsruhe Institute of Technology	Miniaturized Solid-Phase Diversification of a Thiophene Scaffold for Direct-to-Biology Workflows
33 ECP	Ainsley	Beaton	University of Glasgow	Beyond Aurodox: Biosynthetic Engineering Generates Promising New Anti-Virulence Compounds
34	Helen	Bennett	Automation Holdco Ltd.	The Self-Driving Lab: Building the Foundational Infrastructure for Autonomous Science
35	Sophia	Berry	Astrazeneca	BRETSA™ versus BiTSA: A comparison of cellular thermal shift assays for monitoring target engagement in live cells
36	Joshua	Betts	IQVIA	Combining Ion Channel Profiling and MEA Functional Analysis to Improve Prediction of Proarrhythmic Risk
37 ECP	Kay	Bhagabani	Ramona Optics	High Throughput morphometric phenotyping of cortical organoids at plate scale using a multi camera array microscope
38	Sangita	Bhaker	Platelet Services	Optimising in vitro assays for assessing BH3 mimetic and PROTAC DT2216 effects on platelet viability
39 ECP	Urvi	Bhojoo	University Of Toronto	PIXY is a High-Throughput Yeast-Based Platform to Identify Novel Human CYP46A1 Modulators as Candidate Therapeutics for Neurodegeneration
40 ECP	Rose	Bigley	Domainex Ltd	Building a Fragment-Based Drug Discovery Workflow for RNA targets
41	John	Blackwood	Scripta Therapeutics Limited	Transcription Factors as a Roadmap for Drug Discovery
42	Katherine	Blades	University of Leicester	A Roadmap to Better Antibody Validation: Consensus Recommendations from an International Delphi Study
43 ECP	Maria	Blanco	Platelet Services	A Translational Platelet Aggregation Assay for Detecting Therapeutic Antibody-Induced Platelet Liabilities
44				
45	Duncan	Borthwick	Green Elephant Biotech	Enhancing Adherent StemCell Culture with the CellScrew®: a Scalable and Sustainable System for Bioprocessing.
46	Mohamed	Boudjelal	Kaimrc	From Infection to Oncology: AI-Assisted Drug Repurposing Uncovers Anti-Infective and Excipient-Class Compounds as PPAR-A-Linked Anticancer Agents
47	Nathalie	Brandenberg	Readily3d	Advanced organoid manufacturing using volumetric additive bioprinting
48	Robyn	Broad	Indica Labs	Powering ADC Target Development with HALO AI
49	Steven	Brown	Synthace Ltd	A Design of Experiments Toolbox for Assay Development and Optimisation
50	Jarle	Bruun	Oncosyne	Colorectal and pancreatic cancer patient-derived tumoroid phenotypes identify high intra- and inter-patient heterogeneity associated with drug response
51 ECP	Karly	Buchan	University of Oxford	Biochemistry and Biophysics Research Group
52	Richard	Buick	Fusion Antibodies plc	LLM-Driven Library Screening for Discovery of Antibody-based GLP-1R Agonists
53	Louisa	Bursford	Astrazeneca	3Rs Approach to Cell Culture - Implementation of 50% FBS Reduced Media In The Global Cell Bank
54	Paul	Butler	Softprog	Automating Magnetic-Bead Workflows for DNA/RNA, Extra Cellular Vesicle(EV) and Proteomic Sample Preparation
55	Katie	Caldwell	Scantox	Predictive screening tools for genetic toxicology assessment in drug discovery
56	Michelle	Campbell-Ryan	Bio-Rad Laboratories	Expanding Multiplexing Capabilities with TrailBlazer™ StarBright™ Dye Antibody Conjugation Kits
57	Pelin	Candarlioglu	3D and 3Rs Ltd	Translating Innovation into Confident Decisions: Bridging the Gap Between Advanced Cell Model Innovation and Adoption
58 ECP	Annalisa	Carli	Olivia Newton-john Cancer Research Institute	Discovery of HCS58: A Selective HCK Inhibitor with a Novel Binding Mode and Single-Agent Activity in Metastatic Solid Tumour Models

59	Irene	Carlön Andres	The Rosalind Franklin Institute	Correlative FLIM–Cryo-ET Reveals How Viral Protein Processing Drives HIV-1 Entry Competence
60	Oliver	Carney	BMG LABTECH	CoraFluor™ TR-FRET Assay screens for modulators of STUB1 – HSP70 interaction
61 ECP	Hugo	Carrat	ORIA Bioscience	A Medium-Throughput Organelle-Based Toolbox to Interrogate Diverse Drug Targets Across Therapeutic Areas
62	Nikki	Carter	Molecular Devices	From Kit to Screen: Standardized Cardioid Generation Enables Automated Cardiac Drug Discovery Workflows
63 ECP	Laura	Casares Perez	Amphista	Developing Targeted Glue™ degrader therapeutics for oncology: from bench to clinic
64	Kieran	Casey	ChemPartner Europe	Integrated Biologics Discovery Platform: AI-Augmented Design, Experimental Validation and Developability Assessment for Complex Antibody Modalities
65	Jennyfer	Castro Da Silva	University of Campinas (Unicamp)	From Gold(I) Scaffolds to Antiparasitic Drug Discovery: Linking Ligand Design, Chemical Behaviour and Biological Activity
66	Nichole	Cerutti	Bruker Dynamic Biosensors	Unraveling PROTAC Mechanisms Through Biophysical Profiling: From DEL-encoded Library to Cellular Degradation
67 ECP	Michael	Chan Phonphongsavat	Axol Bioscience	Establishing a robust platform for investigating the pro- and anti-inflammatory response of iPSC-derived microglia in drug discovery
68 ECP	Eleni	Charla	Astrazeneca	From Pixels to Prediction: Early Detection of Hepatic Liabilities in Novel Modalities via High-Content Imaging
69	Ravindra	Chaudhari	Nanotemper Technologies	Multi-Parameter In-Solution Characterization of Affinity, Kinetics, Thermodynamics, and Thermal Stability with Monolith™ Omni
70	Viji	Chelliah	Certara	Incorporating design-stage modeling at scale into the early R&D pipeline
71	Jack	Chen	Anivance Ai	From Prediction to Human Evidence: Closing the Loop for Translational Drug Discovery
72	I-Hsun Jack	Chiang	Promatix Biosciences Ltd	Overcoming the Limited Monospecific Target Landscape in Cancer via Discovery of Tumour-Selective AND- and OR-Gate Bispecifics
73	Rawshan	Choudhury	Immundnz	Transforming Pancreatic Cancer Treatment with Targeted Immunomodulatory Therapy
74 ECP	Abdoulatif	Cissé	University Of Liverpool	Opsight: Agentic Experimental Design for Closed-Loop Discovery
75 ECP	Joan	Clark-nicolas	University Of Strathclyde	Chemical Space of Linker-Payloads for Antibody-Drug Conjugates
76	Finola	Cliffe	Hooke Bio Ltd	Expanded Preclinical Testing at Hooke Bio: From 2D & 3D In Vitro Assays to Advanced Human-Relevant Models
77	Michael	Cliford	Analog Devices Inc.	Analog Devices Digital Healthcare
78	Tom	Clough	Avacta	Development of Novel FAP-enabled pre CISION® Peptide Drug Conjugates to Specifically Deliver Payloads to the Tumor Microenvironment
79	Daniel	Cohen	Momentum Biotechnologies	Protein Turnover Atlas
80 ECP	Idoia	Company	Astrazeneca	From Sample Preparation to Insight: An Automated and AI-Enabled Targeted Proteomics Platform for Early Drug Discovery
81	James	Cook	picknmixAI	picknmixAI: the complete life science data and solutions procurement platform accelerating drug discovery around the world
82	Alex	Corbett	University Of Exeter	Ultra-high throughput, high content imaging with the Cairn Research MultiScope
83	Pete	Corish	Aligned Bio Ab	Nanowire-assisted Fluorescence Immunoassay (nFLIA): Enabling ultra-sensitive, low-cost, biomarker assays for pre-clinical drug discovery
84 ECP	James	Craswell	Domainex	Bringing Proteins Together: From Glue Identification to Mechanistic Understanding
85	James	Crichton	University Of Exeter	From Target Validation to Spatial Profiling: Multi-Scale Bioimaging at Exeter
86	Adam	Crosby	3D Bio Tissues Ltd	Advancing Drug Discovery with CytoBoost™: Leveraging Macromolecular Crowding to Maximize Post-Thaw Cell Recovery, Proliferation, and Growth Factor Bioactivity
87	Richard	Cuthbert	Bio-Rad	Single-Particle and mRNA-Encapsulation-Rate Analysis of Lipid Nanoparticle (LNP) Formulations
88	Marc	Davies	New England Biolabs	Cell-free Expression and Rapid Analysis of Single-Chain Antibody Fragments
89 ECP	Rana	Dawood	University Of Nottingham	Versatile intrabody biosensors to detect activation of the atypical chemokine receptor 3 (ACKR3)

90	Johanna	De Castro Arce	Revvity	A Bidirectional Dual-sgRNA System for Uniform and Efficient Multi-Gene CRISPR Perturbation
91	Giovanna	De Filippi	Nanion Technologies	ATLAZ AS A HIGH-THROUGHPUT SYSTEM FOR ADVANCED FUNCTIONAL CELL ANALYSIS TO DEVELOP IMMUNOTHERAPIES
92	Welmoet	De Winter	Zobio	Site-selective SPR fragment screening using SAM-based probes: application to METTL3/14
93	Laura	Defranco	Revvity	Characterising ADC Activity Beyond Cytotoxicity: A Cell-Based Screening Workflow
94	Jan	Detmers	Doppelganger, A Group At Charite Berlin	Single-Cell & Spatial Metabolism: Case Studies in Oncology, Neurology, and Cell Therapy
95	Subhamita	Dey	Cancer Research Horizons	CRISPR at Cancer Research Horizons: From Discovery to Validation
96	Laurence	Dion-Albert	Saguaro Biosciences	Live-Cell Painting with ChromaLIVE Outperforms Fixed Cell Painting in High-Throughput Screening for Drug Discovery.
97	Richard	Dixon	Rancho Biosciences	Closing the Data Gap: A Pre-Competitive Alliance for AI-Ready Drug Discovery Data
98 ECP	Rebecca	Drake	Bicycle Therapeutics	Multimodal targeting of Ephrin type-A receptor 2 in solid tumors using bi-cyclic drug conjugates
99	Audrey	Dubourg	Nuclera Ltd	From DNA to active, monomeric β 1AR receptor in <72 hours, using cell-free synthesis.
100 ECP	Ryan	Duffy	University Of Nottingham	Real-Time TrkC Signalling: Comparison of a Signalling-Deficient TrkC Isoform
101 ECP	Alex	Dulovic	NMI	Multiplexed functional proteomics to decode drug-induced signalling and therapeutic response
102	Lucia	Dunajova	Synthace	Assay miniaturisation and optimisation through multifactorial experimentation
103 ECP	Chloe	Eeles	Domainex Ltd	PureDisc™: A Detergent-Free Platform for Stabilising and Characterising Multi-Pass Membrane Proteins in Polymer Nanodiscs
104 ECP	Abishek	Elangovan	GSK/University of Strathclyde	Utilising the multi-component pore-forming toxin YaxAB to develop a targeted multi-component cytotoxicity system
105	Andrea	Elser	AstraZeneca	Genetic modifier screen in human neurons reveals interaction between SARM1 and rare neuropathies
106	Vesna	Erakovic Haber	Selvita	Integrating Mass Spectrometry Imaging and scRNA-seq to Characterize the Spatial and Cellular Heterogeneity of Colorectal Cancer
107	Johan	Evenäs	Pelago Bioscience	Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR
108	Gemma	Everitt	Astrazeneca	Drug-resistant patient-centric cell models
109	Caroline	Ewens	Institute Of Cancer Research	The Discovery of Potent Inhibitors of the Spliceosomal RNA Helicase DHX8 using Fragment-Based Drug Discovery
110 ECP	Hannah	Fanai	Jss College Of Pharmacy, Ooty	Design and Optimization of Bifunctional Degraders for PARP1: Integrating Molecular Modeling with In Vitro Validation in Resistant Breast Cancer Models
111	Euan	Forbes	New England Biolabs (neb)	A rapid, cell-free dbDNA™ kit enables high-throughput DNA templates for DNA and RNA therapeutics
112	Finbar	Gaffey	Lifearc	Broad phenotypic pathway discovery in motor neurons for Motor Neuron Diseases (MND) therapeutic development
113 ECP	Isabel	Gameiro-Ros	Francis Crick Institute	Automated culturing of stem cell cultures: powering discovery research from genetic perturbation to compound screening
114	Volker	Gatterdam	Miltenyi Biotec B.V. & Co. KG	Focal molography for drug discovery: pooled loading, parallel readout, label-free kinetics at 64-plex
115	Maria	Gayzaeva	Myotwin Gmbh	Serotype-Dependent Transduction Efficiency of AAV-GFP Vectors in Human iPSC-Derived Engineered Myocardial Tissues
116	Talia	Gileadi	Astrazeneca	Steric blocking antisense oligonucleotides targeting the 5'UTR fail to replicate reported translation modulation at non-toxic concentrations
117	Steve	Glavas	Magic Bioprocessing	A Novel Magnetic Solid-Phase Reversible Immobilization Bead with Improved Efficiency and Handling for Nucleic Acid Clean-Up and Size Selection
118	Paulo	Godoy	CELLINK Bioprinting AB	High-Throughput 3D Breast Cancer Models with Tunable Stiffness for Drug Discovery Using BIONOVA X DLP Bioprinting
119 ECP	Anukrati	Goel	University Of Surrey	Modelling interstitial fluid extraction from skin under hypobaric pressure: Translation from adults to infants
120	Hector	Gonzalez	Medtech Barcelona	A SEMI-SOLID ROOM-TEMPERATURE SHIPPING MEDIUM ENABLES SHORT-TERM PRESERVATION OF ADVANCED HUMAN HEPATIC IN VITRO MODELS

121	ECP	Fazel	Gorjipour	Izmir Biomedicine And Genome Center	Spectral Characterization and Development of UV, Direct Fluorescence, and RP-HPLC-FLD Assays for Quantifying the BUB1 Inhibitor BAY-1816032 in Serum to Support Preclinical Development
122		Elnaz	Gozalpour	Pharmaron	Qualifying a human PK projection strategy approach with clinical data: four examples from Phase 1
123	ECP	Sam	Grainger	University Of Edinburgh	Multi-layered Human Tissue Fabrication
124		Chris	Green	Life Science Group	CellShip® - New Opportunities for Short-Term Cell Preservation and Transport
125		Anastasiia	Gryniukova	Astrazeneca	Democratising AI in Drug Discovery: From Productivity Tools to Predictive Experimentation
126	ECP	Nanthana	Gunathilagan	Imperial	Investigating the role of neutral endopeptidase in angiotensin II-induced aortic aneurysm
127		Navina	Günther	AstraZeneca	One machine at a time: the incremental approach to building an automated cell line generation platform
128	ECP	Viktor	Guschin	Karlsruhe Institute Of Technology	Mass Spectrometric Screening of Protein–Ligand Interactions on Droplet Microarrays
129		Thomas	Guttenberger	Metacoder AI	Integrated Heterogeneous Molecular Representations for CYP Inhibition Prediction
130	ECP	Vincent	Hahaut	Alithea Genomics	MERCURIUS™ 1536WP DRUG-seq: A Transcriptomics Platform for Ultra-Scalable Phenotypic Screening
131		Frances	Hall	Instem	Closing the Loop: How Shared Data and AI Improve Translational Decision-Making
132	ECP	Rania Hamdy	Hamdy	UOS	Next-Generation Bcl-2 Inhibitors Targeting Apoptosis in Cancer Cells
133	ECP	Danielle	Hanke	University College London	Development of novel PROTACs targeting the progesterone receptor
134	ECP	Oliver	Hanley	Sunderland University	Mechanistic Insights into Histone Deacetylase 6 Inhibition in Hepatocellular Carcinoma
135	ECP	Harri	Härmä	QRET Technologies	Overcoming protein consumption constraints in thermal shift assays - Low nanomolar protein concentration
136	ECP	Danielle	Harper	Swansea University	Novel Therapeutic Targets in Cancer: Translating RAGE and Calpain Biology into Therapeutics, Biomarkers, and Patient Benefit
137		Kate	Harper	Revvity	Enhancing brightfield high-content analysis: AI-driven segmentation and advanced organoid detection
138	ECP	Saam	Harris	Gsk	Photoporation Enables High-Throughput Antibody-Fluorophore Conjugate Delivery and Spatially Defined CRISPR-Cas9 Knockouts for ADC Studies
139		Tom	Harris-brown	Bit.bio	DEVELOPMENT OF HUMAN iPSC-DERIVED HEPATOCYTES FOR DRUG DISCOVERY, TRANSLATIONAL RESEARCH AND TOXICITY TESTING
140		Sascha	Hartmann	Novalix	Integrated screening and structural approaches for covalent and non-covalent hit discovery
141		Charlotte	Haskayne	Biofortuna	Cell line authentication: a commercial service provider perspective
142		Carl	Haslam	Artios	Connecting Digital Tools to Accelerate Drug Discovery: Integrated Workflow Solutions at Artios
143		Judy	Hawry	Chempartner	Development and Functional Evaluation of Multispecific Antibodies with Single and Multiple Cytotoxic Payloads for Next-Generation ADCs
144		Katie	Headland	Axxam	The Elongator drew the short straw: Discovery of First-In-Class anti-cancer inhibitors targeting the ELP3-trRNA interface
145		Lorraine	Hendry	Independent	A-IMPO: An Explainable AI-Driven Multiparameter Optimization Framework for Blood-Brain Barrier Permeability Prediction and CNS Drug Design
146	ECP	Rowan	Hill	Novo Nordisk & Impellam	Medium-Throughput Human β-Cell Platform Combining cAMP and GSIS Readouts for Characterisation of Novel T2D Therapies
147		Thomas	Hochdörfer	Astrazeneca	Dissecting TRPV4 antagonist mechanisms of action
148		Michelangelo	Trucchi	University Of Pavia	ATP depletion and AMPK activation reveal a receptor-independent anti-steatotic mechanism of MPEP
149		Catherine	Holland	Revvity	Integrated DRUG-seq and Cell Painting Profiling Resolves Mechanistic and Cell-Context-Specific Compound Responses
150		Sanne	Holt	Ncardia services B.V.	Predictive In Vitro Safety Profiling of Antibody–Drug Conjugates Using a Fully Human iPSC-Derived Multi-Tissue Panel
151		Marten	Hornsveld	Crown Bioscience	Expanding Organoid-Based Screening to Characterize Protein Degradar Activity, Resistance, and Translational Potential

152	William	Hotham	Lucid Scientific	Continuous OCR Monitoring Reveals Persistent Loss of Mitochondrial Plasticity in iPSC-Derived Cardiomyocytes Following Sub-Cytotoxic Chemical Hypoxia
153	Jerry	Huang	Scripta Therapeutics	Unbiased phenotypic profiling of iPSC-neurons using self-supervised learning
154	Amber	Insch	Promega Uk	Live-Cell Target Engagement of TRIM21 Using the TarSeer™ BRETSA™ System.
155	Barira	Islam	Certara	A QSAR Panel for Virtual Secondary Pharmacology Profiling: Off-Target Affinity Prediction to Reduce Safety Liabilities
156	Zaynab	Isseljee	Lifearc	Application of Flow Cytometry to Support LifeArc's B-SMArT Antibody Discovery Platform
157 ECP	Michelle	Iwohn	Karlsruhe Institute of Technology	Triggerable Lipid-Based Nanocarriers for Intracellular Nitric Oxide Delivery
158	Molly	Jackson Tankaria	BMG Labtech	Elucidating PROTAC MoA with live cell kinetic monitoring of ternary complex formation and target protein ubiquitination
159	Shushant	Jain	Ncardia	Development of robust iPSC-based α -synuclein, TAU and TDP-43 aggregation pathology in vitro models for drug discovery
160 ECP	Nelli	Jalkanen	Helsinki Institute of Life Science/University Of Helsinki	An iPSC-Derived Neuronal Model of INTS6 Loss-of-Function for Studying Splicing Dysregulation in Neurodevelopmental Disorders
161 ECP	Megan	Jones	UCL	ARUK Drug Discovery Institute: Bridging Academic Innovation and Industry-Standard Drug Discovery for Neurodegenerative Disorders.
162 ECP	Mayur	Kale	University Of Wolverhampton	Differential Anticancer mechanism of Copper and Zinc Diethyldithiocarbamates in Pancreatic cancer
163 ECP	Aizhibek	Karina	University Of Reading	Galleria mellonella as a Preclinical Model for Antibiotic Toxicity Screening: A Foundation for Drug Delivery Research
164	Nahush	Karnataka	Bioskryb	A high-plexity exome solution tailored for sensitive variant detection in single cells
165	Maryia	Karpiyevich	SPT Labtech	Automation and Miniaturisation of RNA-Seq Libraries
166 ECP	Noemi	Karsai	University Of Nottingham	BRET-based characterisation of the HER2 nanobody Q17c-HiLyte488
167 ECP	Claire	Kelly	University Of Nottingham	Dissecting the Subcellular Trafficking and Signalling of PAR2
168 ECP	Mahfuzur Rahma	Khokan	University Of Liverpool	Characterisation of drug non-responsiveness of CYP2C19-metabolised antidepressants in UK biobank participants with both steatotic liver diseases (SLD) and depression
169	Okju	Kim	Atg Lifetech Inc.	Single-organoid RNA sequencing verifies inter- and intra-batch consistency of cardiac organoid production
170	Hyojin	Kim	Astrazeneca	Engineering Fit-for-Purpose Cellular Models Across the Discovery Pipeline
171 ECP	Hannah	Knight	Gsk	A translational 384-well bronchosphere assay to enable high-throughput screening for COPD
172	Andrea	Knight	Anglia Ruskin University	Targeting MYC inhibition by 9aaTADs
173	Uwe	Korth	ICHORtec GmbH	Cooperativity and Conformational Rearrangements in Protein-Protein and Protein-Ligand Interactions
174	Dominika	Kowalczyk	BioAscent Discovery	From Screening to Validation: A Comprehensive Approach to Identifying Covalent Inhibitors for Challenging Targets
175	Florian	Krieger	Evotec SE	Accelerated Hit Finding by Combining High-Throughput Mass Spectrometry Screening with AI-powered Hit Enrichment
176	Dinesh	Kumar	Sygnature Discovery Ltd	From Monocultures to Tricultures: Expanding Human iPSC-Derived Cell Models for Neuroscience Drug Discovery
177	Marcel	Lagedroste	Cube Biotech GmbH	From Copolymer Screening to Plug-and-Play Purification: Automated NativeMP™ Platforms for Membrane Proteins
178 ECP	Yoshitha	Lakshmanan	University Of Wolverhampton	PRECLINICAL DEVELOPMENT OF PLGA-ENCAPSULATED DISULFIRAM MICROPARTICLES FOR TREATMENT OF MALIGNANT MESOTHELIOMA
179	William	LaMarr	Momentum Biotechnologies, Inc.	Investigation of Hits against the GLP-1 Receptor Identified by Affinity Selection Mass Spectrometry: Hit Expansion, Structure-Activity Relationships, and Selectivity Profiling
180 ECP	Joris	Langlois	CAS	Combining human-curated data and machine learning to accelerate drug discovery
181	Sandra	Lara	Astrazeneca	Enabling Human-Relevant SAR Screening: Validation of a Multi-Donor PBMC HTRF Assay for Early Discovery
182	Leif Kongskov	Larsen	Vipergen Aps	DELs in Cells: Direct Discovery of p53–MDM2 PPI Inhibitors

183	ECP	Katie	Lawler	Lifearc	The Development of High-Throughput Experimentation to Interrogate the Structure-Activity Relationship of E3 Ligase Binders
184		Rachel	Lawrence	Cancer Research Horizons	Biophysical Techniques for Target Engagement and Mechanism of Inhibition Studies During Small Molecule Drug Discovery
185		Charles	Leach	Ncardia	Advancing Drug Discovery with Human iPSC-Derived 3D Cardiac and Brain Microtissues
186	ECP	Freya	Leif	Bmg Labtech	Novel nanoBRET-Based Biosensor Enables Comprehensive Screening of eEDCs in Live Cells
187		Aurore	Lejeune-Dodge	Topia Life Science	Smart Molecule AI-driven Generation (SMAG), Precision Design platform for AI-powered Drug Discovery
188		Klaudia	Leśniak	Selvita	Phenotypic Screening by Cell Painting: Improving Reproducibility and Mechanism-of-Action Prediction Through Advanced Normalization and Machine Learning
189		Birgitta	Leuthner	Merck Healthcare KgaA	Mechanism-centric discovery platform for novel molecular glues and PPI inducers
190	ECP	Oscar	Limbachia	Alzheimer's Research UK Drug Discovery Institute UCL	Improving reproducibility when measuring gene expression changes in drug discovery – a showcase of RNA quantification
191		Wanchen	Liu	WuXi Biologics	Bispecific Antibody Discovery: From Strategic Design to Fit-for-Purpose Screening & Characterization
192	ECP	Jessica	Llewellyn	Resolution Therapeutics	Characterisation of a regenerative macrophage therapy (RTX001): stable-fibrosis immunocompetent liver models and a mouse surrogate for pharmacology assessment in end-stage liver disease
193		Pamela	Lochhead	Astrazeneca	RAF conformation biosensors: Dissecting the initiating mechanism of RAS-driven RAF-activation in cells
194	ECP	Nikola	Lonska	Aston University	Replicating Vascular Crosstalk: Engineering Biomimetic 3D Blood Vessel Models using Two-Photon Polymerization and Hydrogels for Drug Discovery
195	ECP	Jyosthna Naik	Lunavath	UCL	A high-content, single-cell assay for quantitative analysis of CFTR-mediated Cl ⁻ and HCO ₃ ⁻ transport
196		Richard	Ma	Fusion Antibodies Plc	OptiMAL: Mammalian Display for Antibody Discovery
197	ECP	Gamila	Maharani (ersan)	Novo Nordisk & Impellam	Human Monocyte-Derived Macrophages as a High-throughput Screening Platform for Innate Immune Regulators of Atherosclerosis
198	ECP	Mahfuza	Maisha	De Montfort University	Cerebellar Kv3.1b Dysregulation and Impaired Motor Coordination in a Subchronic Phencyclidine Model of Schizophrenia
199	ECP	Anna	Malicka	University Of Leeds	Unlocking Exercise Crosstalk: Systemic LRG1 as a Regulator of Skeletal Muscle Degradation
200	ECP	Viktorya	Manukyan	Astrazeneca	Decreasing protein burden in thermal shift assays using Optical Unfolding
201		Nikki	March	Carcinotech	Reproducible Patient-Derived 3D Bioprinted Tumour Models as Predictive Microphysiological Systems for Targeted Cancer Therapy
202	ECP	Vanessa	Marensi	Bangor University	Development and characterization of isoindolones as potential kinase regulators
203		Sebastian	Martewicz	Evotec	Ischemia/reperfusion injury model: an in vitro cellular assay setup with live data acquisition
204		Morag	Martin	Life Sciences Innovation Hub, University Of Dundee	Dundee Life Sciences Innovation Hub: Supporting life sciences companies to grow, scale and thrive
205	ECP	Maria	Martingo	Centre For Biotechnology And Fine Chemistry	Fungal and Squid Chitosan: From Antimicrobial Screening to Biomedical Potential
206		Kennet	Mattsson	Ansa Biotechnologies	Next Generation Enzymatic DNA Synthesis Enables Manufacturability of Long, Complex Constructs
207		Nomagugu	Mbelesi	Concept Life Sciences	Separating WEE1 from PLK1: Structure-Based Design of Selective WEE1 Inhibitors.
208		Owen	McCann	Integrated Dna Technologies	IDT Custom Guide RNAs and CRISPR Off-Target Solutions: From Early Research to Therapeutic Development
209	ECP	Amina	McDiarmid	University Of Edinburgh	Phenotypic and in silico screening in SORL1-/- human neural cells identifies MELK as a putative candidate target for sporadic Alzheimer's Disease
210		Brian	McFerran	BioAscent	Using label-free cellular impedance to characterise GPR35 regulation in an endogenous cell system
211	ECP	Rebecca	McHugh	University of Glasgow	From Microbial Ecology to Drug Discovery: Undecylprodigiosin as a Natural-Product Anti-Virulence Lead against Shiga toxin-producing Escherichia coli
212	ECP	Ragini	Medhi	University of Edinburgh	Decoding the bone marrow niche in acute myeloid leukaemia to identify therapeutic targets using geometric deep learning
213		Rosa María	Mella	Innoprot	Live-Cell Fluorescence Assay to Evaluate drugs Targeting Pathogenic SOD1 A4V Aggregates in ALS

214	Andreas	Meyer-Borgstaedt	Myotwin Gmbh	Decoding the Human Heart: An Automated High-Content Platform for Parallel Assessment of Force, Stiffness, Calcium Handling, and Electrophysiology in Engineered Myocardial Tissues
215	Alfira	Miftakhova	University Of Reading, School Of Pharmacy	Formulation and Evaluation of a Licorice Extract Lip
216	Hayato	Miyoshi	FUJIFILM Corporation	Balm for Potential Application in Orolabial Herpes
217 ECP	Karthik	Mohanraj	Magnitude Biosciences	Comprehensive Evaluation of Acute and Long-Term Drug-Induced QT Prolongation Using Human iPSC-Derived Cardiomyocytes and Multi-Electrode Arrays
218	Laurent	Molveau	Hp	The Magnitude Way: Accelerating Hit-to-Lead Decisions with Whole-Organism Profiling
219	Fabio	Montisci	Ccdc	HP Inkjet Technology for Low Volume Reagent and Single Cell Dispensing
220 ECP	Rebekah	Mooney	Ulster University	Knowledge-Based Conformational Sampling and Ternary Assembly of PROTACs
221 ECP	Benjamin	Moore	University of Nottingham	Divergent Viability and Apoptotic Responses to Pharmacological NR4A Modulation Reveal Context-Dependent Vulnerabilities in Melanoma
222	Benjamin	Moore	Excellerate Bioscience	Developing CRISPR-Cas9 edited HUVEC/TERT2 cell lines to investigate the dynamics of endogenous VEGF-A and its receptors in endothelial cells upon endotoxin stimulation.
223 ECP	Alexandra	Morse	CN Bio	Dual-Approach Mitochondrial Toxicity Profiling: Integrating High-Throughput Screening with Functional Bioenergetic Analysis
224	Elizabeth	Mouchet	Inoviv	Predicting human drug-drug interactions using a dual organ Gut/Liver microphysiological model system
225 ECP	Stefanie	Muethel	Lonza Cologne GmbH	A novel assay to quantify 3R and 4R tau isoform imbalance in human CSF via multiplexed IP-MS
226	Niamh	Mullooly	Novo Nordisk	Clinical Translation of Nonviral Gene Editing: Efficient Electroporation of CD34+, NK, and T Cells in large volume
227 ECP	Dorian	Muntean	University Of Oxford	Accelerating Drug Discovery Through a Modular, Shared Automation Hub
228	Yaarub	Musa	Genedata	Beyond Bacteria: Repurposing β -Lactams for SARS-CoV-2 Main Protease Inhibition
229	Manisha	Naik	Topia Life Sciences	Enhancing Analysis Efficiency in High-Throughput Intact Mass Spectrometry
230	Jyothish	Nair	Seven Nodes	AI-Driven MPO for Smarter Drug Discovery
231	Elena	Naumovska	StemX Bio	Causal Boolean Network Modelling Reveals Immunotherapy Targets Overlooked by Differential Expression and Generates Testable Intervention Hypotheses in Lung Adenocarcinoma
232	Marta	Nawrocka	Pharmaron UK	Human iPSC-derived pancreatic microtissues for predictive metabolic drug screening and pancreatic safety testing
233	Libby	Naylor	Genscript	Evaluation of an IDAS2-PAMPA Two-Stage In Vitro System for Assessing Passive Permeability of Small Molecules
234 ECP	Ani	Nejatfard	Portal Bio	4-Day Sequence-to-Data: Accelerating AI-Driven Protein Discovery via Integrated Cell-Free Workflow
235	Ryan	Nelson	Nuclera	A Versatile Mechanoporation Platform for Live-Cell Drug Discovery and High-Efficiency Cell Engineering
236	Michelle	Newman	Genedata Ltd	Rapid Cell-Free Validation of AI-Generated Antibody Libraries
237	Nikolaos	Nikolaou	Pixl Bio	Ensuring Data Quality, Traceability, and Interpretability with Automated Assay Data Workflows
238	Yannick	Nossin	Cell Signaling Technology	Development of a Fully Isogenic iPSC-Derived Multicellular Liver Model for Disease Modelling and Toxicity Screening
239	Alison	Obergrussberger	Nanion Technologies GmbH	Development of Chimeric Monoclonal Antibodies to Facilitate Low-Plex, Multi-Species Imaging of Key Brain Cell Markers
240 ECP	Habon	Odawaa	Takeda Uk	High-throughput Automated Patch-Clamp Analysis Reveals Altered Excitability and Variation of Ion Channel activity in ALS iPSC-Derived Motor Neurons
241 ECP	Alex	Ondrea	Novo Nordisk	Optimising Drug Discovery: A Dual Screening Platform for HIF-2 α Mutant Inhibitors
242	Yosuke	Ono	University of Exeter	Medium Throughput Fluorescence-Based Pipeline for Genetic Screening of Therapeutic Targets in Human Adipocytes
243	Trine	Østerbye	Samplix ApS	Establishing human disease models using CRISPR/Cas9-based genome editing technologies in zebrafish
244	Raul	Pacheco Gomez	Malvern Panalytical	Xdrop®: High-Throughput screening in antibody discovery
				From candidate selection to a robust biologic: An orthogonal biophysical workflow using ITC, GCI, Zetasizer Core, DSF and DSC

245	Dimitri	Pappaioannou	Fluosphera	Early Identification of Interstitial Lung Disease Risk While Measuring ADC Efficacy in a Human Systemic In Vitro Platform
246	Christian	Parker	Novartis	Development and Screening for Inhibitors of the NLRP6 Inflammasome
247 ECP	Matt	Parkin	University of Dundee / BioAscent Discovery	A Modular Photo-Redox Assisted Direct-to-Biology Approach for Bifunctional Degradер Synthesis and Discovery
248	Adrien	Pasquier	Francis Crick Institute	SemaCyte-Enabled Multiplexed Compound Toxicity Profiling
249	Svetlana	Pasteuning	Product Management	A contractility platform for 3D engineered muscle tissues
250	Chandni	Patel	ARUK DDI UCL	Identifying Novel PI3Kdelta Modulators
251	Saleha	Patel	Constructive Bio	Reprogramming the genetic code for the recombinant production of next-generation biotherapeutics
252 ECP	Karla	Paterson	Screenin3d	Testing drug efficacy and toxicity on human 3D models at scale
253	Claudio	Pathe	Astrazeneca	Scaling ADC Profiling: A 384-Well Toolbox of Dual-Reporter Bystander and 3D Spheroid Assays
254	Kamila	Pawlicka	Chempartner	Antibody–Oligonucleotide Conjugates: From Stochastic Conjugation to Site-Specific Click Chemistry
255	Adam	Peall	Arctoris	Arctoris in the Loop: Closing the Design-Make-Test-Analyse Cycle with Automated Drug Discovery
256 ECP	Ennio	Pecaver	Cancer Research Horizons	Fluorescence Polarisation under Assay Constraints: Mechanistic and Screening Utility and Limitations
257 ECP	Sonia	Pedro	University Of Nottingham	Breaking the Barrier: Translating Ocular Formulations into Non-Invasive Treatments
258	Jason	Pembroke	Domainex	Characterisation of reversible and irreversible covalent inhibitors using an LC-MS based covalent fragment screening workflow
259 ECP	Gina	Pereira	Lifearc	Targeted Protein Degradation at LifeArc: Characterising underexplored E3 Ligases
260	Vinit	Pereira	ImmuONE	De-Risking ADCs: In Vitro Detection of Off-Target Lung Liabilities Using High-Content Imaging
261	Marco	Pinheiro	Bio-Techne	BromoCatch: A Compact Self-Labeling Protein Tag for Imaging and Protein Manipulation
262	Joao	Pisco	Lifearc	Discovery and characterisation of PROTACs recruiting novel E3 ligases
263 ECP	Kamila	Podpłórska	Medical University Of Gdańsk	Stress, Bugs, and Sulfa Drugs: An IRE1α-Directed Framework for Prostate Cancer
264	Jon	Popplewell	Carterra	HT-SPR Screening and Kinetic Characterization of Small-Molecule Binders Using Carterra Vega™ and Comparison with AI Binding Predictions
265	Joe	Potter	Sygnature Discovery	From inhibition to degradation: Targeting STAT6 and type 2 inflammatory signalling in asthma and atopic dermatitis
266 ECP	Alpana	Prajapat	Sartorius	High-Throughput Assessment of Antibody Internalization
267	Robyn	Presland	Domainex Ltd	Redefining Direct-to-Biology Through Integrated Multistep Medicinal Chemistry
268	Steve	Price	Selvita	Integrated Cell-Free and Cellular Assays for Induced Proximity Drug Discovery: From Protein Interactions to Functional Degradation
269 ECP	Amberene	Qayyum	University of Nottingham	Investigating the Ability of Nanoluciferase and mGOLD-tagged Nanobody AD101 to Target Active-State A2A Receptors in Living Cells.
270	Clement	Quan	Alitheia Genomics	MERCURIUS™ 1536 DRUG-seq Generates Reproducible Ultra-High-Throughput Transcriptomic Perturbation Datasets That Decipher Compound Mechanisms of Action and Toxicity Pathway Activation
271	Valentina	Quarantotti	AstraZeneca	High Dimensional Experimentation (HDE) promotes sustainable assay development in primary cells
272	Omar	Qureshi	Celentyx	Translational neuroinflammation drug discovery using human microglial models
273 ECP	Simran	Rai	Fairjourney	Developability-Guided Multi-Display Engineering Enables Rapid Generation of Differentiated Bispecific Antibody Leads
274	Arwa	Raies	Astrazeneca	DrugnomeAI 2.0: Machine-learning framework for druggability prediction of 19K protein-coding genes
275	Rebecca	Ram	Lush Prize (www.lushprize.org)	The Lush Prize - funding innovative non-animal, new approach methods in drug discovery and life sciences research

276	Carmen	Ramos	Fundacion Medina	Synergizing Multicellular Spheroids/Organoids, Microbial Natural Products, High Content Screening, and AI for Triple Negative Breast Cancer Therapy Discovery	
277	ECP	Huma	Raza	University College London	Investigating the Selective Interactions of Lipid Nanoparticles with Molecular Targets: A Preliminary Study Towards Targeted Gene Delivery
278	Nikki	Re	Sygnature Discovery	Development of Human Th17 and Th1 Polarisation Models for Compound Screening	
279	Bradley	Redford	Zageno	ZAGEN0 - from protocol to cart	
280	Reuben	Reed	Fluidic Sciences Ltd.	Machine learning guided interaction analysis	
281	ECP	Rinta	Reji	Institute Of Cancer Research	Targeting PAX8 in High-Grade Serous Ovarian Cancer: A High-Throughput Drug Repurposing Screen for Degradars and Inhibitors
282	Charlotte	Renaut	Cambridge Bioscience	Evaluating STAT6-targeting degradars using complementary biochemical and cell-based assays	
283	ECP	Paul	Reuß	Goethe University Frankfurt	E-ASMS based high throughput HIT identification delivers novel BTB-Domain binding compounds
284	Suzanne	Riches	Revvity	Enhanced Automated Hepatocyte Counting	
285	Nicole	Rivers	www.bit.bio/	Optical pooled CRISPR screen allows parallel single-cell morphological, proteomic, and perturbation profiling in human iPSC-derived ioMicroglia.	
286	Matija	Rojnik	Brainzell Ab	Patient-derived brain organoid platform for early drug discovery of Alzheimer's disease	
287	ECP	Lucille	Rossiaud	Syntopia	Scaling human biology for AI-driven drug development: Towards relevant biology, controlled environment, multimodal data, and scalability. Native-Tissue cAMP Assays For Endogenous GPCR Target Validation in Kidney and Pancreas
288	Sarah	Routledge	Gifford Bioscience	BaseScope™ duplex assay enables same-slide detection of short RNA targets including isoforms	
289	Natalie	Rowe	Bio-techne Spatial	Accelerating Anti-Biotherapeutic Tool Antibody Development with Bio-Rad's Pioneer Select Platform	
290	Paul	Royle	Bio-Rad	EZH2 Targeting in Lung Adenocarcinoma: Tumor-Cell Remodeling and Stromal Signaling	
291	Wioletta	Rozpędek-Kamińska	Medical University of Lodz	AID2: Rapid and Reversible Protein Depletion for Functional Target Validation in Drug Discovery	
292	Yuka	Ryomoto	National Institute Of Genetics	High-throughput screening services at FIMM-HTB lab	
293	Jani	Saarela	University Of Helsinki	Comparison of the targeting behavior of two exchangeable perilipins, PLIN3 and PLIN4 to lipid droplet	
294	ECP	Bayane	Sabbagh	University Of Montpellier	In Silico Design and Synthetic Planning of Novel METTL3 Inhibitors Based on STM2457 for High-Risk Neuroblastoma
295	ECP	Noor E	Sahar	University Of Hertfordshire	FBDD at Pharmaron: Library Enhancement and Case Study
296	Francois	Saint-dizier	Pharmaron	Biosurfactants enhance structural and colloidal stability in model proteins relevant to therapeutic formulations: a multidimensional analysis	
297	ECP	Zartashia	Saleem	University of Huddersfield	High-Throughput Drug Response Profiling in Head and Neck Squamous Cell Carcinoma Using Miniaturized Droplet Microarrays
298	ECP	Vicky Loretta	Schiling	KIT, IBCS-FMS	Scalable Fabrication of Standardized Multicellular Assembloids using Droplet Microarrays for Bottom-Up Tissue Assembly
299	ECP	Maike	Schliephake	Karlsruhe Institute Of Technology	Pooled CRISPR Screening for Drug Target Discovery in Primary Human Macrophages
300	Henrik	Schmidt	Myllia	Affinity selection mass spectrometry speeds ligand discovery for PPI-targets and membrane proteins	
301	ECP	Anselm	Schneider	Nuvisan ICB GmbH	Scalable 3D Human Neural Microtissues for Neurotoxicity Screening and Functional CNS Safety Assessment
302	Christine	Schwenk	InSphero AG	Multiplexed 3D Screening to Accelerate Therapeutic Indication Selection in Drug Discovery	
303	Gregory	Segala	FluoSphera SA	A Novel β-Lactone Biosynthetic Gene Cluster from an Atacama Desert Extremophile	
304	Antonio	Serrano	Bioicus Lab	Combined Phenotypic and RNA-Targeted Screening Identifies Potent Inhibitors of Coronavirus Discontinuous Transcription	
305	Libera	Sessa	IRBM	Fast-Track Closed-Loop Experimentation with AI-Driven Automation on Stuntman	
306	Nicola	Shaw	Unchained Labs		

307	Jonathan	Sheard	Centre For Human Specific Research	Human Specific Research Regional Communities: Supporting the Adoption of Human-Focused Science Through Localised Knowledge Sharing and Collaboration.
308	Jack	Shepherd	Pharmalegacy Laboratories	Aggregation to Translation: Building Better Models of Neurodegeneration
309	Jeff	Shi	MedchemExpress	MedchemExpress- your strategic partner for ADCs, Antibodies & Recombinant protein
310	Alex	Sim	Screenin3d	UpScale3D perfusion: facilitating dynamic drug testing at scale
311	Manoja	Sivakumar	Bmg Labtech	PARP1 and PARP1-HPF1 Complex association with inhibitors assessed using kinetic fluorescence polarisation measurements
312 ECP	Katie	Smith	Alcyomics	Skimune® A Powerful Human-Centric Platform For The Identification Of T cell Engager Immunotoxicity
313 ECP	Jaden	Smith	University Of East Anglia	Different Tumour Microenvironment Stress Factors Induce Differential Effects on Tunneling Nanotube Formation in Lung Adenocarcinoma Cells
314	Harriet	Smith	CN Bio	Long-Term Evaluation of siRNA Therapeutics in a Human Liver Microphysiological System.
315	Rhiannon	Smith	Immunocore	Automating Discovery from the ground up: concept to practice in T cell engager discovery
316 ECP	Zuzanna	Sokolowska	University Of Nottingham	TrkB.T1 and TrkC.T1 isoforms have a distinct pharmacology from full-length TrkB and TrkC
317	Abel	Sousa	Astrazeneca	Evaluating Statistical Methods for DNA-Encoded Library Enrichment Analysis Using Simulated Data
318 ECP	Eve	Stalker	Broken String Biosciences	Performance benchmarking of INDUCE-seq®: an unbiased, genome-wide assay for the detection of gene-editing associated breaks
319	William	Steele	RxCelerate	Accelerating Antibody Discovery Through Computational Epitope Mapping
320	Joshua	Stewart	Fluidic Sciences	Detection of Antibody-Secreting Cells in Cyto-Mine® Chroma: Comparison of Bead-Based and FRET Antigen-Specific Assays
321 ECP	Adithi	Sundaresh	Hilife, University Of Helsinki	One Mechanism, Many Diagnoses: Towards a Common Treatment Strategy for Chromatin-Linked Neurodevelopmental Disorders
322	David	Sykes	Z7 Biotech Ltd	Pharmacology and Target Engagement of Ulocuplumab, a Clinical Anti-CXCR4 Antibody
323	Marcel	Taillefer	Astrazeneca	From Design to Analysis. Automated, AI-assisted end-to-end DoE workflow
324 ECP	Zher Yin	Tan	University of Dundee	Towards LRRK2-Targeted Molecular Glues
325	Simon	Teague	Pharmaron	Optimizing Intestinal Tissue Exposure of Locally Acting Drugs Using an In Vivo-Informed PBPK Modelling Approach
326	Ana	Teixeira-Silva	Astrazeneca	AI-Assisted Review of a Human 3D Structural Cardiotoxicity Assay
327 ECP	Thilini	Tharushika	University Of Moratuwa	GraphMD: A Multiscale Geometric Deep Learning Framework for Protein-Ligand Binding Affinity and Conformational Dynamics Prediction
328 ECP	Kyle	Thompson	Bioascent Discovery	Functional 5-HT2A/5-HT2B Receptor Reserves Influence Agonist Pharmacology: Implications for Pre-Clinical Drug Safety Profiling
329	Aizhan	Tolebay	University Of Reading	Replacing Vertebrate Preclinical Screening: Planaria as a Predictive Model for Local Anesthetics
330	Bence	Tóth	Mcule	PURCHASABLE BUILDING BLOCKS SUITABLE FOR DEL CHEMISTRY – CURATED FROM THE MCULE DATABASE
331	Jasmine	Trigg	Sartorius	Confocal Live-Cell Imaging Enables Spatial and Kinetic Resolution of Immune Cell Killing in 3D Spheroid Assays
332 ECP	Crystal	Tsui	Portal Biotechnologies	Optimizing the Right Candidates: Live-Cell Validation before Medicinal Chemistry
333 ECP	Millie	Tyler	AstraZeneca	Integrating Human Genetics and Functional Genomics to Define Causal Disease Biology Across Diverse Cellular Contexts
334	Guido	Uhlenbrock	Bruker Dynamic Biosensors	Integrated Biophysical Analysis of Fc–FcR Binding, Affinity, and Avidity in Antibody Therapeutics
335 ECP	Robert	Ulrich	Bicycle Therapeutics	Empowering Small-Scale Biophysics: Transforming Operational Capacity and Unlocking Innovation Through Custom Automation
336	Piet	Van Der Graaf	Certara	Model-Informed First-in-Human Dose Selection for an In Vivo BCMA CAR T Therapy in Multiple Myeloma
337	Sarika	Vanarse	Capgemini	Therapies of Tomorrow: Why Technology and Business Transformation Matter as Much as the Science Navigating a Future Where Medical Knowledge, AI-Powered Discovery Platforms, and Business Transformation Converge to Close the Gap Between Breakthrough

338	ECP	Ian	Vandenbussche	Trince	Assessing Plate Consistency of LumiPore-Based Intracellular Delivery in Drug Screening
339		Daniel	Vaughan	Optics11 Life	Mechanical Cues As Functional Markers Of 3D In Vitro Models
340	ECP	Teigan	Veale	University Of Exeter	Defining the role of pkd1 and pkd2 in zebrafish cardio-renal system function
341		Tarun	Vemulkar	Semaron	From Binding to Specificity: Rapid Image-Based Biologics Screening Across Multiple Cell Models with SemaCytes
342	ECP	Mugdha	Vengurlekar	University Of Wolverhampton	Investigating the Influence of PMCAs on the Tumorigenesis and Drug Resistance of Glioblastoma
343	ECP	Dragone	Vincenza	Merck Healthcare Kgaa, Darmstadt. Germany	Direct-to-Biology: Streamlining Synthesis and Testing for PROTACs and Beyond
344	ECP	Abishana	Vishuvanathan	University Of Hertfordshire	Effects of Age on Potassium Channel Modulation of Murine Gastrointestinal Motility
345		Simon	Vyse	Astrazeneca	Scalable long-term assay in Patient-Derived Organoids to interrogate novel drug combination opportunities
346		Malte	Wachsmuth	Bruker Luxendo GmbH	From High Throughput to High Resolution - Bruker Fluorescence Microscopy Solutions
347	ECP	Lewis	Walker	Axol Biosciences	Characterization of human-iPSC-derived motor neuron disease model for ALS drug discovery
348		Nicolas	Walker	Twinvitro.bio	From human-relevant to patient-relevant: an agentic platform for the optimal management of NAMs in preclinical drug discovery
349		Catherine	Wark	BMG LABTECH Ltd	Screening for inhibitors of the ubiquitination regulator and anticancer target CSN5 using a HTS fluorescence polarisation method
350		Jitka	Waterman	Diamond Light Source	THE DRUG DISCOVERY WITH MACROMOLECULAR X-RAY CRYSTALLOGRAPHY AT DIAMOND LIGHT SOURCE
351	ECP	Elle	Watson	Newcastle University	Development of DNA-PK-targeting PROTACs to maximise DNA-PK blockage in advanced prostate cancer
352	ECP	Jessica Lee	WATTS	Malvern Instruments	Enhance mAb formulation Characterisation using the Zetasizer Core
353		Louise	Watts	Axol Biosciences Ltd	New Approach Methodologies (NAMs): assessing cardiotoxicity and neurotoxicity in vitro using human iPSC-derived cells
354		Chris	Wellaway	Pharmaron	Interrogating Different Induced Proximity Modalities
355		Katie	West	Cytiva	From purification to binding analysis: an integrated workflow for tag-free protein studies in narcolepsy drug discovery
356		Marta	Westwood	Pharmaron	Advancing Drug Discovery Through Biophysical Characterization of Diverse Therapeutic Modalities
357		David	Whalley	IQVIA Laboratories	An Integrated SAMDI-ASMS Screening Cascade for the Identification and Biophysical Validation of Small-Molecule Binders Against a Challenging Transcription Factor Target
358	ECP	Maya	Wilson	Arctoris Ltd	Automated 1536-Well Sample Preparation: Overcoming Miniaturization Bottlenecks for High-Throughput DRUG-seq
359		Cornelia	Wilson	Canterbury Christ Church University	Evaluation of mesoporous silica nanoparticles for drug delivery in breast and lung cancer using the CAM model.
360		Kirsty	Winn	Selvita	High Content Screening as a Window to Understanding and Modulating Ageing Pathologies for Drug Discovery
361	ECP	Andrew	Wood	Vernalis	Correlation between SPR binding kinetics of PROTAC ternary complexes and cellular degradation efficiency
362		HaoLun	Wu	Rxcelerate	Unlocking Hidden Metastates to Expand the Druggable Proteome
363		Renee	Xu	ACROBiosystems	Developing a Single B Cell Platform to Accelerate Antibody Discovery and Screening
364	ECP	Hazal	Yuceturk	University Of Sunderland	Exploring the 3Ns (neuroprotection, neuroplasticity, and neurorepair) potential of psychedelics: ER Stress modulation in health and Alzheimer's Disease
365	ECP	Laraib	Zaidi	University of Exeter	Testing the Translational Power of Zebrafish to Study Human Heart Failure
366		Ash	Zarkan	Biotryp Therapeutics	Antibiofilm Therapies for Bacterial Infections
367	ECP	Albert	Zhang	Fujifilm	AI-Assisted Transformation of PD-L1 Inhibitory Peptides into Small Molecules Using Amino Acid Mapping Descriptor and Activity Improvement through Structure-Based Drug Design
368	ECP	Yiyun	Zhang	University Of Exeter	Modelling TDP-43 Proteinopathy in hiPSC-derived Skeletal Muscle and Neuromuscular Assembloids

369	Daniel	Ziemianowicz	MO:RE GMBH	Standardizing and automating high throughput 3D cell culture and downstream applications with the MO:BOT
370	ECP	Katie	Zimmermann	Immunocore
371	PierreJ	Zindy	Evotec -	Improving and Accelerating Hit Identification using High Throughput Chemistry (HTC) combined with Direct to Biology (D2B)
372	ECP	Louisa	Zolkiewski	Apconix
373	Irene	Zubiri	Momentum	ProteomeScout-HT: high-throughput DIA proteomics for proteome-wide screening of molecular glue degrader libraries, toward integrated degradomics and interactomics profiling